Journal of Comparative Effectiveness Research

Papers
(The H4-Index of Journal of Comparative Effectiveness Research is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more174
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis46
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea45
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database35
Journal of Comparative Effectiveness Research : 2022 year in review30
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis26
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis25
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy23
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis23
Engaging veterans in the research process: a practical guide23
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary23
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain22
Access in all areas? A round-up of developments in market access and health technology assessment: part 1020
Corrigendum20
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies19
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 2019
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study18
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis18
0.066792011260986